Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 2/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.52 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.52 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.51 |
| ▸ | CALCR | P30988 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31707422 | 0.86 | NMUR2 (0.59) | IL23RKEAP1NMUR2NMUR1 | |
| SCHEMBL30607271 | 0.86 | EP300 (0.58) | KEAP1RAMP3CALCR | |
| SCHEMBL30485544 | 0.86 | NMUR2 (0.59) | EPHA2KEAP1NMUR2NMUR1RAMP3 | |
| SCHEMBL29403705 | 0.86 | IL23R (0.55) | EPHA2IL23ROPRD1 | |
| SCHEMBL30605203 | 0.85 | OPRD1 (0.52) | IL23ROPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL30906428 | 0.85 | EPHA2 (0.59) | EPHA2IL23RRAMP3CALCR | |
| SCHEMBL30571151 | 0.85 | EPHA2 (0.58) | EPHA2KEAP1RAMP3CALCR | |
| SCHEMBL29865083 | 0.85 | OPRM1 (0.62) | EPHA2OPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL30063804 | 0.85 | EPHA2 (0.58) | EPHA2OPRD1OPRM1KEAP1NMUR2 | |
| SCHEMBL29865041 | 0.85 | OPRM1 (0.62) | EPHA2OPRD1OPRM1NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | EPHA2 4580/4885IL23R 3167/4885OPRD1 4574/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | EPHA2 4580/4885IL23R 3167/4885OPRD1 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.